Progress in treatment of MLL-rearranged leukemia in children

国际输血及血液学杂志 Pub Date : 2019-03-20 DOI:10.3760/CMA.J.ISSN.1673-419X.2019.02.014

Z. Gu, J. Xia, Tian-yu Li

引用次数: 0

Abstract

MLL-rearranged leukemia is caused by rearrangement of the MLL gene located on chromosome 11q23, which is one of the common types in childhood leukemia. It can be clinically manifested as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome, and treatment-related leukemia. At present, the treatments of MLL-rearranged leukemia are combined chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). The survival rate has been improved, but the outcomes and prognosis of most MLL-rearrangement leukemia are not excellent. Targeted therapy and immunotherapy are expected to become new treatments for the disease, which improve prognosis and survival rate. This article reviews the progress in the treatment of MLL-rearranged leukemia, and highlights the progress and potential of targeted therapy in recent years. Key words: Leukemia; Gene rearrangement; Antineoplastic combined chemotherapy protocols; Hematopoietic stem cell transplantation; Molecular targeted therapy; Immunotherapy; MLL gene

查看原文本刊更多论文

儿童mll重排白血病的治疗进展

MLL重排白血病是由位于11q23染色体上的MLL基因重排引起的，是儿童白血病的常见类型之一。临床表现为急性淋巴细胞白血病(ALL)、急性髓系白血病(AML)、骨髓增生异常综合征和治疗相关性白血病。目前，mll重排白血病的治疗主要是化疗联合异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation, alloo - hsct)。虽然生存率有所提高，但多数mll重排白血病的预后并不理想。靶向治疗和免疫治疗有望成为新的治疗方法，改善预后和生存率。本文综述了mll重排白血病的治疗进展，重点介绍了近年来靶向治疗的进展和潜力。关键词:白血病;基因重排;抗肿瘤联合化疗方案;造血干细胞移植;分子靶向治疗;免疫治疗;MLL基因

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

国际输血及血液学杂志

自引率

0.00%

发文量

10610

期刊介绍： The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.